TransMedics Group (TMDX) Scheduled to Post Quarterly Earnings on Tuesday

TransMedics Group (NASDAQ:TMDX) will issue its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.05) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.22. The firm had revenue of $81.20 million for the quarter, compared to analysts’ expectations of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The business’s quarterly revenue was up 158.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) EPS. On average, analysts expect TransMedics Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

TransMedics Group Stock Performance

TMDX opened at $86.51 on Tuesday. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The business’s fifty day simple moving average is $82.85 and its 200 day simple moving average is $73.74. TransMedics Group has a 52 week low of $36.42 and a 52 week high of $99.63.

Analyst Ratings Changes

A number of equities analysts recently weighed in on TMDX shares. JPMorgan Chase & Co. raised their price objective on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a report on Tuesday, February 27th. Piper Sandler initiated coverage on shares of TransMedics Group in a report on Thursday, March 28th. They issued an “overweight” rating and a $95.00 price objective for the company. Morgan Stanley increased their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, Oppenheimer boosted their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 27th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 4,000 shares of TransMedics Group stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total value of $380,480.00. Following the sale, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,047,155.44. The sale was disclosed in a filing with the SEC, which is available through this link. In other TransMedics Group news, CEO Waleed H. Hassanein sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $95.09, for a total value of $1,141,080.00. Following the completion of the sale, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,044,932.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Waleed H. Hassanein sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total value of $380,480.00. Following the transaction, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,047,155.44. The disclosure for this sale can be found here. Insiders sold 117,078 shares of company stock valued at $9,972,971 in the last 90 days. Insiders own 6.70% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.